Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalolitovorellizumab plus eribulin in advanced triple-negative breast cancer (second-line and later)
ChiCTR2500111069Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of epalolitovorellizumab, eribulin in breast cancer, sponsored by Yantai Yuhuangding Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
epalolitovorellizumaberibulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500111069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111069.